Omadacycline Tissue Penetration for Tolerable Mycobacterial Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics for treating mycobacterial infections, such as tigecycline, are limited by adverse gastrointestinal effects and require long-term administration, making them unsuitable for effective and tolerable treatment of mycobacterial infections.
Innovation Solution
The use of omadacycline, a 9-aminomethyl tetracycline derivative, which demonstrates high activity against mycobacterial species and can be administered orally with fewer side effects, allowing for effective treatment of mycobacterial infections, particularly those caused by NTM and Mycobacterium tuberculosis, by penetrating infected tissues and cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tigecycline is used to treat mycobacterial infections, then antibacterial activity is improved, but gastrointestinal side effects worsen
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of tetracycline compounds to create novel derivatives with improved pharmacological properties. Specifically, the invention develops tetracycline compounds with altered molecular parameters that enhance antibacterial activity against mycobacteria while reducing gastrointestinal side effects through modified absorption and metabolism characteristics
2Reliability
If long-term antibiotic administration is used to treat mycobacterial infections, then treatment efficacy is improved, but patient tolerability worsens
Solution Approach 1:
The invention changes pharmacokinetic parameters of tetracycline compounds through structural modification, achieving prolonged half-life and sustained tissue concentrations that enable less frequent dosing. This improves patient tolerability while maintaining treatment efficacy over the extended therapy periods required for mycobacterial infections
Solution Approach 2:
The patent converts the typically harmful accumulation of tetracycline compounds in the body into a beneficial feature by designing compounds with improved tissue penetration and sustained release characteristics. The modified compounds accumulate selectively in infected tissues at therapeutic concentrations while minimizing systemic side effects, transforming potential toxicity into sustained efficacy
3Reliability
If frequent dosing is used to maintain effective antibiotic levels, then treatment effectiveness is improved, but treatment complexity worsens
Solution Approach 1:
The patent modifies pharmacokinetic parameters including half-life, tissue distribution, and clearance rates of tetracycline compounds through structural changes. These modifications enable the drugs to maintain effective concentrations for longer periods, reducing dosing frequency from multiple daily administrations to once or twice daily regimens, thereby simplifying treatment protocols
Data Source
AI summary
The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.